Clinical Trial

Neurocognitive Effects of Extended-Release Methylphenidate in Healthy Adults

Completed Early Phase 1
View on ClinicalTrials.gov →
Summary
This study evaluated the effects of methylphenidate (MPH), a stimulant medication commonly used to treat attention deficit hyperactivity disorder (ADHD), in healthy adults without ADHD. Although MPH is sometimes used by students and athletes to improve concentration or performance, its true benefits and risks in healthy individuals are uncertain. The purpose of this study was to determine whether short-term use of MPH improves thinking ability, physical performance, cardiovascular function, balance, muscle strength, or heart safety in healthy adults. In this randomized, double-blind, placebo-controlled crossover study, 28 healthy adult participants received either MPH (20 mg daily) or a placebo for 14 days, followed by a washout period and then the alternate treatment. Participants underwent repeated testing of heart rate, blood pressure, exercise capacity, balance, muscle strength, cognitive function, and heart electrical activity (ECG).
Trial Details
NCT Number NCT07742631
Lead Sponsor University of Witwatersrand, South Africa
Conditions Healthy Adult Male and Female Volunteers
Enrollment 30 participants
Start Date 2023-02-06
Primary Completion 2024-04-15 (estimated)
Study Completion 2024-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-03